skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine (Code C107169)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine

Definition: An allogeneic melanoma cell vaccine derived from a cell line with high expression of melanoma associated antigens and genetically modified to express both HLA-A2 and 4-1BB ligand, with potential immunostimulating and antineoplastic activities. Upon administration, the 4-1BB ligand of the allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine binds to 4-1BB on activated T-lymphocytes, which induces a strong immune response against HLA-A2 positive melanoma cells.

Label: Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine

NCI Thesaurus Code: C107169 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL449429  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 750454
PDQ Open Trial Search ID 750454 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C107169
Semantic_Type Cell
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom